Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
4 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Boundless Bio, Inc.’s names, not what it holds today.
Patents granted
4
4 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against none in 2024 and 3 in 2023
Applications published
13
1 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals3
Organic fine chemistry1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Boundless Bio, Inc. its own name
named as the applicant on its applications, in US
13 publishedBOUNDLESS BIO, INC. its own name
US, as the owner printed on each patent
0 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Mar 11, 2025 | 12,246,017 | Replication stress pathway agent compositions and methods for treating cancer | Pharmaceuticals | BOUNDLESS BIO, INC. |
| Jul 25, 2023 | 11,707,462 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | Organic fine chemistry | BOUNDLESS BIO, INC. |
| May 9, 2023 | 11,642,345 | Replication stress pathway agent compositions and methods for treating cancer | Pharmaceuticals | BOUNDLESS BIO, INC. |
| Jan 10, 2023 | 11,547,711 | Replication stress pathway agent compositions and methods for treating cancer | Pharmaceuticals | BOUNDLESS BIO, INC. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Jan 2, 2025 | 2025/0002486 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | Pharmaceuticals | Boundless Bio, Inc. |
| Dec 26, 2024 | 2024/0425490 | SULFAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | Pharmaceuticals | Boundless Bio, Inc. |
| Aug 29, 2024 | 2024/0285614 | PHENOL RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | Organic fine chemistry | Boundless Bio, Inc. |
| Jul 11, 2024 | 2024/0228459 | WEE1 INHIBITORS AND USES THEREOF | Organic fine chemistry | Boundless Bio, Inc. |
| May 16, 2024 | 2024/0158383 | RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | Organic fine chemistry | Boundless Bio, Inc. |
| Oct 5, 2023 | 2023/0310423 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | Organic fine chemistry | Boundless Bio, Inc. |
| Aug 31, 2023 | 2023/0272485 | REPLICATION STRESS PATHWAY AGENT COMPOSITIONS AND METHODS FOR TREATING CANCER | Pharmaceuticals | Boundless Bio, Inc. |
| Aug 10, 2023 | 2023/0248728 | REPLICATION STRESS PATHWAY AGENT COMPOSITIONS AND METHODS FOR TREATING CANCER | Pharmaceuticals | Boundless Bio, Inc. · patent 12,246,017 granted from it |
| Apr 20, 2023 | 2023/0124417 | COMPUTER-IMPLEMENTED METHODS FOR QUANTITATION OF FEATURES OF INTEREST IN WHOLE-SLIDE IMAGING | Computer technology | Boundless Bio, Inc. |
| Apr 6, 2023 | 2023/0104315 | METHOD OF IDENTIFYING EXTRACHROMOSOMAL DNA SIGNATURES | Biotechnology | Boundless Bio, Inc. |
What it applied for, 2024 to 2025: Organic fine chemistry 3 · Pharmaceuticals 2.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.